Incyte completes $1.25B acquisition of Vega Therapeutics, adding Phase 3 VWD asset VGA039

INCYTE CORP

• Acquisition adds VGA039, a novel monoclonal antibody in Phase 3 for von Willebrand disease (VWD).
• Upfront payment of $1.25B; up to $750M in additional sales milestones for Star Therapeutics.
• VGA039 has Breakthrough Therapy, Fast Track, orphan drug, and rare pediatric disease FDA designations.
• Transaction expected to be recorded as a one-time R&D expense in Q3 and full year 2026.
• VGA039 is in pivotal Phase 3 VIVID-6 study; potential first once-monthly subcutaneous prophylactic for VWD.